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Biological context
Catechol O-methyltransferase (COMT, EC 2.1.1.6) is a 
ubiquitous bisubstrate magnesium-dependent enzyme 
found in plants, animals and microorganisms. It catalyses 
the transfer of a methyl group from S-adenosyl-L-methio-
nine (SAM) to one of the hydroxyl oxygen atoms (prefer-
entially the 3-hydroxyl) in a catechol substrate (Mannisto 
and Kaakkola 1999). Physiological substrates of COMT 
are catecholamine neurotransmitters such as dopamine, 
noradrenaline, adrenaline and their metabolites. COMT 
also methylates catecholic steroids such as 2-hydroxyestra-
diol as well as a range of other catecholic compounds 
including neuroactive drugs such as L-dopa, α-methyldopa 
and isoproterenol (Ball et al. 1972; Borchardt 1980; Guld-
berg and Marsden 1975). COMT inhibition is a means of 
treating Parkinson’s disease, schizophrenia and depression 
(Fava et al. 1999; Harrison et al. 2015; Kiss and Soares-da-
Silva 2014). There are two isoforms of human COMT: sol-
uble cytoplasmic COMT (S-COMT), which is mainly intra-
cellular, and a membrane-bound form (MB-COMT), which 
has a single-span helix contained within a 50 amino acid 
extension at the N-terminus. Genetic studies have demon-
strated that both soluble and membrane-bound isoforms 
of human COMT are coded by a single gene, using two 
separate promoters, assigned to chromosome 22q11.2 (Ten-
hunen et  al. 1994). However, S-COMT possesses Km val-
ues for catecholamines that are ~15 times higher than those 
reported for MB-COMT, and in addition has a lower ain-
ity for the SAM cofactor (Lotta et al. 1995). Several X-ray 
crystal structures have been solved for COMT enzymes 
from a range of organisms together with diferent substrate/
inhibitor complexes. S-COMT has a single domain α/β-
folded structure with eight α-helices and seven β-strands. 
The N-terminal region is composed of three α-helices, the 
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central section has ive α-helices arranged around a ive-
stranded parallel β-sheet, while the C-terminal part consists 
of two antiparallel β-strands. The active site is located on 
the outer surface of the enzyme and includes a SAM bind-
ing pocket and a substrate binding site situated in the vicin-
ity of a bound catalytic Mg2+ ion (Vidgren et al. 1994).
Methods and experiments
Protein expression and puriication
The human S-COMT construct used in this study has a 12 
residue hexa-histidine tag and cloning sequence positioned 
at the N-terminus (MHHHHHHENLYFQG…). The canon-
ical S-COMT sequence begins at Q1 and here the canoni-
cal S-COMT numbering system is used throughout. This 
construct also contains valine (rather than methionine) at 
the allelic polymorphism position located at residue 108 of 
S-COMT (Lachman et  al. 1996; Rutherford et  al. 2008a). 
A synthetic, codon-optimised human S-COMT gene cloned 
into a pEX-A2 plasmid was purchased from Euroins 
Genomics. This gene was then cloned into a pET21a plas-
mid for expression purposes. 2H,15N,13C-labelled protein 
was expressed using Escherichia coli strain BL21(DE3) 
(Stratagene) in a deined isotopically labelled minimal 
media, following the protocol of Reed et  al. (2003). The 
cells were grown at 37 °C with shaking until A600 nm reached 
0.6–0.8, were cooled to 30 °C and induced by adding 
isopropyl-β-D-thiogalactopyranoside (IPTG) to a inal con-
centration of 0.4 mM. Cells were harvested 12–14 h after 
induction using centrifugation at ~6000  rpm for 20  min 
at 4 °C. The cell pellet was collected and stored at −20 °C 
until further use. All puriication steps were performed at 
4 °C. Harvested cells were allowed to thaw and were then 
resuspended in cell lysis bufer comprising 50 mM sodium 
phosphate, 300 mM NaCl, 10 mM imidazole, pH 7.4 and 
containing cOmplete™, Mini, EDTA-free protease inhibi-
tor tablets (Roche) (one tablet per 50 mL of bufer), 10 µg/
mL DNase and 10 mM MgCl2. Cells at a concentration of 
~100 mg of cell pellet/mL were lysed on ice by sonication 
for 15 cycles of pulsation for 15 s with 45 s intervals. The 
cell extract was then separated by ultracentrifugation at 
~48,000×g (20,000 rpm) for 30 min at 4 °C in a Beckman 
Coulter J26-XP Avanti centrifuge using rotor JA 25.50. The 
supernatant was then iltered using 0.45  μm syringe il-
ters (Sartorius Mechatronics UK Ltd) before loading onto 
a 5 mL His-Trap FF ainity Ni-Sepharose column (GE 
Healthcare) connected to an AKTA puriication system 
(GE Healthcare) that had been previously washed with at 
least ive column volumes of iltered and degassed water 
and equilibrated by washing with ten column volumes of 
iltered and degassed cell lysis bufer. Proteins bound to the 
Ni resin were eluted with a gradient of 10–300  mM imi-
dazole in cell lysis bufer over 16 column volumes or with 
a two-step elution comprising eight column volumes of 
10 mM imidazole in cell lysis bufer and then eight column 
volumes of 300  mM imidazole in cell lysis bufer. Frac-
tions showing S-COMT content, observed as a peak in UV 
absorbance at 280 nm, were pooled, checked for purity by 
SDS–PAGE, concentrated by VivaSpin (10,000 MWCO, 
GE Healthcare) and loaded onto a Superdex 75 26/60 
size exclusion column (Fisher Scientiic) connected to an 
AKTA puriication system. The column was washed with 
at least 1.5 column volumes of iltered and degassed water 
and equilibrated with two column volumes of iltered and 
degassed gel iltration bufer (50 mM Tris–HCl bufer pH 
7.5 containing 50 mM NaCl and 10 mM DTT) prior to use. 
S-COMT was eluted with two column volumes of gel il-
tration bufer, and then checked for purity by SDS–PAGE. 
Chromatograms (280  nm detection) monitoring the size 
exclusion puriication show two separated peaks, which 
correspond to monomeric and dimeric S-COMT as con-
irmed by native gel electrophoresis and mass spectrom-
etry (not shown). The fraction of monomer was typically 
40–80 % of total puriied S-COMT. The monomeric form 
of the protein was used for further investigations. Once 
puriied, back exchange to amide protium atoms in perdeu-
terated S-COMT was promoted by overnight incubation in 
50 mM Tris–HCl, 10 mM DTT, pH 9.0 at 25 °C, followed 
by VivaSpin-mediated bufer exchange at 4 °C into 50 mM 
Tris–HCl, 10  mM DTT, 50  mM NaCl, pH 7.5. Protein 
concentrations were estimated by absorbance at 280  nm 
measured with a NanoDrop (ε280 = 24,785 M
−1 cm−1) and 
Bio-Rad protein concentration assays, following the manu-
facturers’ protocols. NMR experiments were performed 
on S-COMT samples obtained within 1  day of puriica-
tion. The stable isotopically-labelled compounds 15NH4Cl 
(99 %), 13C6,
2H7-D-Glucose (U-
13C6, 99 %; 1,2,3,4,5,6,6-
d7 97–98 %) and 
2H2O (99.8 %) were purchased from 
Goss Scientiic. All other reagents, including S-adenosyl-
L-methionine (SAM) and 3,5-dinitrocatechol (DNC) were 
purchased with the highest purity available from Sigma-
Aldrich (Dorset, UK) and used as received.
NMR experiments
All NMR measurements were performed at 298 K, using 
standard pulse sequences on an 800 MHz Bruker Avance 
III NMR spectrometer itted with a TCI cryoprobe 
equipped with Z gradients and TopSpin software ver-
sion 3.2 housed in the Manchester Institute of Biotech-
nology. NMR samples containing 0.5  mM 2H,15N,13C-
labelled human S-COMT, 5 mM SAM, 5 mM DNC and 
2.5 mM MgCl2 in 50 mM Tris–HCl bufer, 50 mM NaCl, 
10 mM DTT, 2 mM NaN3, pH 7.5 were loaded into 5-mm 
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Fig. 1  2D 1H-15N TROSY spectrum of the human 
S-COMT:SAM:DNC:Mg2+ complex recorded at pH 7.5 and 298 K. 
The assignments of backbone amide resonances are indicated by 
residue type and sequence number, following the canonical S-COMT 
nomenclature. Residues of the cloning sequence are referred to by 
their residue type and position in the cloning tag together with a tag 
indicator (e.g. N9tag)
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diameter NMR tubes. 2H2O was added to the protein sam-
ples (10 % v/v) to allow a deuterium lock and 0.5 % v/v 
trimethylsilyl propanoic acid (TSP) was added as a refer-
ence signal. 1H chemical shifts were referenced relative 
to the internal TSP signal, whereas 15N and 13C chemi-
cal shifts were indirectly referenced using nuclei-speciic 
gyromagnetic ratios. For the backbone 1H, 15N and 13C 
resonance assignment, standard Bruker 1H-15N TROSY 
and TROSY-based 3D HNCA, HNCACB, HN(CO)
CACB, HN(CA)CO and HNCO spectra were acquired 
using non-uniform sampling with a multidimensional 
Poisson Gap scheduling strategy with sinebell weighting 
(Hyberts et  al. 2013). A 30  Hz (0.4  ppm) resolution in 
the carbon dimension was obtained after processing. The 
HNCO spectrum, with one peak per residue in the carbon 
dimension was obtained with 230 hypercomplex points, 
whereas spectra with two peaks per residue (HNCA, 
HN(CO)CACB, HN(CA)CO) were obtained with 460 
hypercomplex points and the HNCACB spectrum with 
four peaks per residue was obtained with 920 hypercom-
plex points.
Resonance assignments and data deposition
Backbone 1HN, 
15N, 13Cα, 
13Cβ and 
13C’ chemical shifts were 
assigned for S-COMT in the S-COMT:SAM:DNC:Mg2+ 
complex using standard triple resonance methodology 
(Gardner and Kay 1998). Spectra were processed with 
TopSpin software version 3.2. Peak picking and frequency 
matching was performed within CCPNMR Analysis ver-
sion 2.4 (Vranken et  al. 2005) and the backbone assign-
ments were checked independently using a simulated 
annealing algorithm employed by the “asstools” assign-
ment program (Reed et  al. 2003). The backbone 1H, 15N 
and 13C chemical shifts have been deposited in the BioMa-
gResBank (http://www.bmrb.wisc.edu/) under the BMRB 
accession code 26848.
Excluding the ten proline residues and the irst eight res-
idues of the N-terminal cloning tag from the 233-residue 
S-COMT protein sequence, 205 out of a total of 215 resi-
dues were assigned in the 1H-15N TROSY spectrum of the 
S-COMT:SAM:DNC:Mg2+ complex (Fig. 1). In total, 97 % 
of all backbone resonances were assigned (95 % of 1HN, 
95 % of 15N, 98 % of 13Cα, 97 % of 
13Cβ and 98 % of 
13C’ 
nuclei). There is evidence for exchange dynamics occurring 
on a slow NMR timescale due to the presence of duplicate 
spin systems in the 1H-15N TROSY and 3D correlation 
spectra. Cis–trans proline isomerisation at P221 is the most 
likely source of conformational dynamics responsible for 
spin system duplication at A219 and G220. There is also 
spin system duplication for Q1 and G2, where the cloning 
tag meets the S-COMT sequence.
There are ten residues that remain unassigned in the 
1H-15N TROSY spectrum (D3, G43, D44, G47, V53, 
Fig. 2  Two orthogonal representations of the backbone assign-
ments mapped onto the X-ray crystal structure of the human 
S-COMT:SAM:DNC:Mg2+ complex (PDB: 3BWM; (Rutherford 
et al. 2008b)). Assigned residues are coloured blue, proline residues 
are coloured red, and all unassigned residues are coloured yellow. 
SAM and DNC are shown as CPK-coloured sticks and the magne-
sium ion is indicated as a green sphere
Fig. 3  Backbone secondary structure prediction of S-COMT in the 
S-COMT:SAM:DNC:Mg2+ complex obtained with TALOS+ (Shen 
et al. 2009) using the backbone 1HN, 
15N, 13Cα, 
13Cβ and 
13C’ chemi-
cal shifts. The secondary structure prediction is shown as red bars 
for α-helices and blue bars for β-strands, with the height of the bars 
representing the probability of the secondary structure assigned by 
the software. The secondary structure derived from the X-ray crystal 
structure of the human S-COMT:SAM:DNC:Mg2+ complex (PDB: 
3BWM; (Rutherford et al. 2008b)) is reported below the panel in the 
same colour representation
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Q58, M76, G83, S187 and G214). From the crystal struc-
ture (PDB: 3BWM; (Rutherford et  al. 2008b), Fig.  2), 
D3, Q58, G83, S187 and G214 are located at the surface 
of the protein, mostly in solvent exposed loops, and as 
a consequence the 1H-15N TROSY correlations are likely 
to be attenuated beyond detection by fast exchange with 
solvent. Several residues in the third α-helix (G43-Q58) 
and fourth α-helix (G70-R78) have 1H-15N TROSY 
peak intensities that are broadened by conformational 
exchange; speciically these are: K48, I49, D51, I54, E56, 
V74, R75 and A77. Such exchange behaviour points to 
dynamics occurring on the millisecond timescale in this 
region of the protein, which are the likely source of the 
broadening beyond detection of the 1H-15N TROSY cor-
relations of G43, D44, G47, V53 and M76. An overlay of 
S-COMT crystal structures (PDB: 4PYI, 3A7E, 3BWM, 
4PYQ, 4P7J) shows that the last turn of the second 
α-helix (C33-K36) and the irst turn of the third α-helix 
(G43-K46) has positional heterogeneity resulting from 
the active site loop (E37-V42) occupying alternative con-
formations. One consequence of these conformational 
diferences requires that the sidechain donors of R75 
coordinate the sidechain acceptors of D44 and D51 dif-
ferently, which might account for the exchange broaden-
ing behaviour observed for these residues, together with 
residues in their immediate vicinity.
The secondary structure content of S-COMT 
was predicted by uploading the backbone 1HN, 
15N, 13Cα, 
13Cβ and 
13C’ chemical shifts of the 
S-COMT:SAM:DNC:Mg2+ complex to the TALOS+ 
webserver (Shen et  al. 2009). Figure  3 compares the 
predicted secondary structure for the solution complex 
with the secondary structure observed in the crystal 
form of the complex. These data are in very good agree-
ment, which indicates that the solution conformation is 
very similar to the protein structure observed in crys-
tals, and provides conidence in the assignments of the 
S-COMT:SAM:DNC:Mg2+ complex.
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